Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$589.99 USD

589.99
691,572

+4.25 (0.73%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q4 Earnings

by Zacks Equity Research

Hologic's (HOLX) Molecular Diagnostics sales are likely to have been affected by the significant drop in demand for COVID-19 testing.

    Sweta Killa headshot

    5 Solid Dividend Growth Stocks for Q4

    by Sweta Killa

    Boise Cascade (BCC), RCI Hospitality (RICK), Iron Mountain (IRM), McKesson (MCK) and National Fuel Gas (NFG) seem compelling picks for Q4 amid volatility.

    Derek Lewis headshot

    Should Investors Consider These 3 Warren Buffett Purchases?

    by Derek Lewis

    Many people turn to the Oracle of Omaha when looking for stocks to add. After all, it's easy to understand why after seeing his track record.

    Is a Beat Likely for DexCom (DXCM) This Earnings Season?

    by Zacks Equity Research

    DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

    by Zacks Equity Research

    We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.

    Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

    by Zacks Equity Research

    Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

    Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.

    Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View

    by Zacks Equity Research

    Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.

    Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

    Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)

    by Zacks Equity Research

    Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

    IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.

    STERIS (STE) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.

    Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up

    by Zacks Equity Research

    Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

    Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

    Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.

    BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence

    by Zacks Equity Research

    BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.

    3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

    Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.

    Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

    by Zacks Equity Research

    West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

    What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

    by Zacks Equity Research

    Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.

    Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

    by Zacks Equity Research

    Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.

    Snehadri Nag headshot

    Grab These Top 4 Defensive Stocks to Beat the Market Doldrums

    by Snehadri Nag

    Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water (CWCO), Archer Daniels Midland (ADM) and McKesson (MCK) with strong prospects to beat the market volatility.

    Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for JPUS